Neurology

Developed Formulas
Benefits
  • Improvement of motor and non-motor symptoms in PD patients
  • Protection & restoration of intestinal membrane integrity
  • Counteraction of inflammation and oxidative stress
  • Gut dysbiosis counteraction
  • GABA producer
Neurology
Ready to market
Neurology
Clinical test
Neurology
In vitro test
Neurology
Hydrosoluble powder
Neurology
Allergen Free
Neurology
Real time stability
Components

Bifidobacterium animalis subsp. lactis BS01 (LMG P-21384)

Bifidobacterium adolescentis BA02 (DSM 18351)

Bifidobacterium longum BL03 (DSM 23233)

FOS

Label Claim

Food supplement with probiotic strains

Effective nutraceutical combination
Scientific Rationale

Parkinson’s Disease (PD) is one the most common neurodegenerative disorder characterized by motor (bradykinesia, rest tremor, and rigidity) and non-motor symptoms, that affects 2–3% of the population ≥65 years of age. The disease originates from the loss of dopaminergic neurons in the substantia nigra and the accumulation of misfolded alpha-synuclein protein in surviving neurons. Alphasynuclein also accumulates in the gut and it may spread to the central nervous system via the vagus nerve3, explaining why non-motor symptoms, like constipation, can precede the onset of classical motor symptoms for several years.

The gut microbiota is increasingly recognized as key modulators of the central nervous system (CNS) by producing substances, as GABA and serotonin, whose imbalances are linked to disease progression. Additionally, in preclinical settings, probiotics have demonstrated the ability to counteract neuronal loss and alpha-synuclein aggregation, important pathological markers of PD. Notably, preliminary in vitro studies have revealed the immunomodulatory properties of probiotics.

Different evidences have shown that probiotics have positive effects on both motor and non-motor symptoms in Parkinson’s disease (PD). Thus, restoring their levels could be a promising therapeutic target.

NEUROVIVA is based on 3 strains with sinergical activities on constipation, oxidation, inflammation and GABA production. Parkinson’s patients are painful and usually constipated.

In addition, PD symptoms develop due to decrease of GABA.

BS01 and BL03 are effective in constipated patients. BS01 is capable to counteract oxidative stress in PD as shows the study from patients with Parkinson’s disease and Inhibition of bacterial overgrowth.

All the strains are able to produce GABA as demonstrated in vitro. BA02 has antioxidant activity. Moreover BS01 and BL03 have showed high protection of epithelial cells.

The formulation was evaluated in a randomized, placebocontrolled, double-blind clinical trial involving patients with Parkinson’s disease. Participants received the treatment once daily for a period of 12 weeks.

At the end of the study, the results showed a significant improvement in both motor and non-motor symptoms. In particular, benefits were observed in gastrointestinal disturbances, quality of life, and cognitive profile. Furthermore, the treatment was associated with a reduction in inflammation levels.

Bibliography
  • Magistrelli L et al. (2019) Probiotics May Have Beneficial Effects in Parkinson’s Disease: In vitro Evidence. Front. Immunol. 10:969.
  • Magistrelli L, Contaldi E, Visciglia A, Deusebio G, Pane M, Amoruso A. The Impact of Probiotics on Clinical Symptoms and Peripheral Cytokines Levels in Parkinson’s Disease: Preliminary In Vivo Data. Brain Sci. 2024 Nov 15;14(11):1147.
  • Visciglia A,et al. Genetic and Functional Analysis of Probiotics:
  • Investigating Neurotransmitter Production and Health-Related Traits in Parkinson’s Disease Poster from Mind Mood & Microbes 2025.
Associations